Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Daiichi Sankyo is a Japanese drugmaker that invents and sells medicines, most famously cancer drugs.
Daiichi Sankyo is a Japanese pharmaceutical company that discovers, develops, and sells prescription medicines. For most of its history it was a fairly traditional drugmaker selling things like blood-pressure pills and cholesterol drugs. Today its future rides on one thing: antibody-drug conjugates, or ADCs. These are cancer medicines built like guided missiles. A lab-made antibody homes in on a protein found mostly on cancer cells, and it drags a powerful chemotherapy payload along with it. The chemo stays mostly quiet until the missile locks onto its target, then it hits the tumor hard while sparing more of the healthy tissue than old-school chemo would. That is the pitch, and it has turned Daiichi Sankyo from a mid-sized Japanese firm into one of the most watched oncology companies in the world.
The star of the show is a drug called Enhertu, which the company developed with AstraZeneca. It treats certain breast, lung, and stomach cancers, and it has posted striking results in trials, including in patients whose tumors are relatively low in the protein it targets. Enhertu's sales have climbed fast and it is now a multibillion-dollar product, which matters because blockbuster drugs pay for everything else a drugmaker does. Daiichi Sankyo has a pipeline of other ADCs behind it, and it has struck big licensing deals with partners — including Merck — that bring in large upfront cash and future payments if the drugs work. The business is simple to describe and hard to do. Invent a molecule, run years of expensive clinical trials, persuade regulators in each country to approve it, then persuade doctors and insurers to pay for it. Daiichi Sankyo earns money by selling those approved drugs, mostly in Japan, the United States, and Europe, and it splits costs and profits with partners on some of its biggest products. Its old-line medicines, sold in Japan and other Asian markets, still generate steady cash, but they are not where the growth is. The risks are real. A drug company's fortunes can flip on a single trial result, and competition in oncology is fierce — rivals like Pfizer and Roche are chasing the same ADC idea. Enhertu also carries serious side effects, including a lung condition that regulators monitor closely, so safety scares are a genuine threat. And because Daiichi Sankyo depends heavily on a handful of products, any stumble in a key trial or a patent expiration years down the road hits hard. The upside is that if the ADC platform keeps delivering, the company has a rare position: a Japanese drugmaker with a genuinely world-leading cancer franchise, not just a regional pill seller.
Saved answer · last researched 23 Oct 2026
see a list of the most recent 300 searches below: